Masimo (MASI)
(Delayed Data from NSDQ)
$111.53 USD
-2.74 (-2.40%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $111.67 +0.14 (0.13%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.53 USD
-2.74 (-2.40%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $111.67 +0.14 (0.13%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum C VGM
Zacks News
Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results (revised)
by Zacks Equity Research
The published data sets prove that Abbott's (ABT) MitraClip ensures the sustenance of long-term quality of life for patients of secondary or functional mitral regurgitation (MR).
Stryker (SYK) Scales a New 52-Week High on Solid Prospects
by Zacks Equity Research
The key growth-driving factor for Stryker (SYK) in the past year has been increasing net sales from each of its three major business segments.
Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results (Revised)
by Zacks Equity Research
The published data sets prove that Abbott's (ABT) MitraClip ensures the sustenance of long-term quality of life for patients of secondary or functional MR.
Boston Scientific (BSX) Rides on Acquisitions, Innovation
by Zacks Equity Research
Boston Scientific (BSX) takes a big leap forward by closing the buyout of Millipede and inking a deal to purchase BTG plc.
Boston Scientific's EP Arm Gets a Lift From Study Success
by Zacks Equity Research
The positive result regarding Boston Scientific's (BSX) LUMINIZE RF Balloon Catheter is expected to help the company further advance with the procedures to clinch a CE Mark for the instrument.
Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results
by Zacks Equity Research
The published data sets prove that Abbott's (ABT) MitraClip ensures the sustenance of long-term quality of life for patients of secondary or functional mitral regurgitation (MR).
Omnicell's Global Expansion on Track, Stiff Competition Ails
by Zacks Equity Research
Although Omnicell (OMCL) is steadily expanding in the Middle East and South African belts, it sees a greater uptake of technologies across other regions of the world.
Integra's Duragen Secures Japanese Nod to Drive Global Growth
by Zacks Equity Research
Despite facing adverse foreign exchange volatility across its international business, Integra LifeSciences (IART) can successfully eye certain key developments on foreign shores.
Here's Why You Should Buy Masimo (MASI) Stock Right Now
by Zacks Equity Research
Masimo (MASI) announces CE marking of its Next Generation SedLine brain function monitoring for pediatric patients.
Abbott (ABT) Gets FDA Approval for Expanded Use of MitraClip
by Zacks Equity Research
The FDA approval is expected to strengthen Abbott's (ABT) structural heart business.
Tandem Diabetes (TNDM) Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Tandem Diabetes Care's (TNDM) growth in pump shipments drives the top line significantly.
Cardiovascular Systems Gains on Global Growth & Innovation
by Zacks Equity Research
Cardiovascular Systems (CSII) hopes that new product menu will deliver minimum 10% growth in its core business during the second half of fiscal 2019.
Edwards Lifesciences Makes Investments in Heart Failure Space
by Zacks Equity Research
The two transactions align with Edwards Lifesciences' (EW) goal of making the most innovative medical care available to patients of structural heart disease.
Haemonetics' Plasma Unit Grows, Global Expansion on Track
by Zacks Equity Research
Haemonetics' (HAE) Plasma arm steadily witnesses solid growth in the fiscal third quarter on 16% revenue rise at constant currency.
Hill-Rom's Buyout of Voalte to Bolster Digital Connectivity
by Zacks Equity Research
Hill-Rom (HRC) anticipates Voalte acquisition to be modestly dilutive to its adjusted EPS in fiscal 2019.
GNC Holdings Global Business Strong, Domestic Sales Weak
by Zacks Equity Research
Within same store, GNC Holdings (GNC) performs dismally at domestic franchise locations.
Tandem Diabetes Signs as an Insulin Pump Vendor in Canada
by Zacks Equity Research
Tandem Diabetes' (TNDM) insulin pump seems to be a strategic fit and well-timed from its massive uptake by the diabetic patients in Canada.
Invitae (NVTA) Scales a New 52-Week High on Solid Prospects
by Zacks Equity Research
One of the key growth drivers for Invitae (NVTA) is an increase in billable tests over the past year.
ResMed's New Brightree Suite to Boost Home Infusion Business
by Zacks Equity Research
ResMed's (RMD) Brightree suite upgrade will help uplift business operations by easily meeting compliance needs and offering the best quality patient care.
Resmed (RMD) to Acquire HB Healthcare to Treat Sleep Apnea
by Zacks Equity Research
ResMed (RMD) to expand in CPAP and respiratory care market in Korea.
Cooper Companies (COO) Hits 52-Week High on Solid Prospects
by Zacks Equity Research
Cooper Companies' (COO) revenues across CooperVision and CooperSurgery see growth.
Walgreens Boots Rides on Retail Pharmacy USA, Strategic Deals
by Zacks Equity Research
Walgreens Boots' (WBA) Retail Pharmacy USA division benefits from comparable prescription growth and a strong retail prescription market.
Henry Schien Buys North American Rescue, Expands Medical Arm
by Zacks Equity Research
Henry Schien (HSIC) believes that acquisition of NAR's business will offer multiple growth opportunities and promising business synergies.
Medtronic's Mazor Robotics Aid Growth, Rising Costs Ail
by Zacks Equity Research
We are upbeat about the recently-concluded buyout of Mazor Robotics, which is likely to solidify Medtronic's (MDT) position in the spine surgery space.
Medtronic Launches Grafton DBM Bone Grafting Product in Japan
by Zacks Equity Research
Grafton DBM to strengthen Medtronic's (MDT) foothold in Japan.